原研机构 |
在研机构 |
非在研机构- |
权益机构- |
最高研发阶段临床1期 |
首次获批日期- |
最高研发阶段(中国)早期临床1期 |
特殊审评- |
开始日期2025-02-28 |
申办/合作机构 首都医科大学宣武医院 [+1] |
开始日期2024-11-25 |
申办/合作机构 |
开始日期2023-12-20 |
申办/合作机构 ![]() [+1] |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
多发性硬化症 | 临床1期 | 中国 | 2025-02-28 | |
重症肌无力 | 临床1期 | 中国 | 2025-02-28 | |
视神经脊髓炎 | 临床1期 | 中国 | 2025-02-28 | |
慢性炎症性脱髓鞘性多发性神经病 | 临床1期 | 中国 | 2025-02-28 | |
狼疮性肾炎 | 临床1期 | - | 2024-11-25 | |
B细胞淋巴瘤 | 临床1期 | - | 2023-12-20 | |
前体B细胞急性淋巴细胞白血病 | 临床1期 | - | 2023-12-20 | |
风湿性疾病 | 临床阶段不明 | 中国 | 2024-07-15 | |
难治性B细胞淋巴瘤 | 临床申请批准 | 中国 | 2025-04-17 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
N/A | 4 | 鏇顧廠醖廠製餘醖蓋鏇(艱襯鏇艱鏇淵夢艱遞壓) = The most commonly observed grade 3 or 4 adverse events within the first few weeks were neutropenia, lymphopenia, hepatic dysfunction, fever, and fatigue. Neutropenia and lymphopenia were attributed to the lymphodepletion conditioning regimen. All patients experienced only grade 1 cytokine release syndrome (CRS), manifesting as fever that persisted for 2–3 days. No patients developed immune effector cell-associated neurotoxicity syndrome (ICANS) or GVHD during treatment. 鏇製遞網壓築襯齋積餘 (遞蓋廠窪膚壓製齋膚鏇 ) | 积极 | 2025-05-08 | |||
N/A | 3 | 鬱鏇窪鏇鏇壓鹽齋衊憲(鹽夢衊鬱糧鑰醖遞製壓) = the significant improvement in the clinical response index scores for the two diseases, respectively, and supported by the observations of reversal of inflammation and fibrosis. 鏇獵鑰淵廠衊鹽鏇鏇願 (選觸鏇構構餘鏇範鏇鹹 ) 更多 | 积极 | 2024-07-15 |